On April, 18 WallStreet anticipated Novartis AG (NYSE:NVS)’s earnings release, as reported by RTT. Analysts forecast 3.13 % diference or $1.24 from the $1.28 EPS from 2018. If the current EPS of $1.24 is accurate, NVS’s profit could hit $2.87 billion. Wall Street forecasts 0.00 % EPS growth as of April, 18. NVS touched $93.42 during the last trading session after $0.24 change.Novartis AG is uptrending after having risen 8.33% since March 23, 2018. NVS has 2.81 million volume or 43.43% up from normal. The stock outperformed the S&P500 by 3.96%.

Novartis AG (NYSE:NVS) Ratings Coverage

In total 3 analysts cover Novartis (NYSE:NVS). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NYSE:NVS)’s analyst reports since November 19, 2018 according to StockzIntelligence Inc. On Tuesday, December 11 the stock of Novartis AG (NYSE:NVS) has “Buy” rating given by Jefferies. The company rating was upgraded by Cowen & Co on Monday, November 26. In Monday, November 19 report Goldman Sachs upgraded the stock to “Conviction Buy” rating.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.The company has $216.55 billion market cap. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.17.36 is the P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

For more Novartis AG (NYSE:NVS) news published recently go to: Globenewswire.com, Seekingalpha.com, Bizjournals.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today’s Competitive Landscape – GlobeNewswire” published on February 25, 2019, “Novartis goes ex-dividend on Monday – Seeking Alpha” on March 01, 2019, “BioMed Realty plants flag in East Bay with acquisition of Novartis site – San Francisco Business Times – San Francisco Business Times” with a publish date: March 20, 2019, “Sandoz chief departs, spin-off looming? – Seeking Alpha” and the last “Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback – Benzinga” with publication date: March 22, 2019.